AU2012308993A1 - Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients - Google Patents

Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients Download PDF

Info

Publication number
AU2012308993A1
AU2012308993A1 AU2012308993A AU2012308993A AU2012308993A1 AU 2012308993 A1 AU2012308993 A1 AU 2012308993A1 AU 2012308993 A AU2012308993 A AU 2012308993A AU 2012308993 A AU2012308993 A AU 2012308993A AU 2012308993 A1 AU2012308993 A1 AU 2012308993A1
Authority
AU
Australia
Prior art keywords
dose
patient
days
benzimidazol
methylpiperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012308993A
Other languages
English (en)
Inventor
Suraj Prakash ANAND
Catherine Wynnette REDDICK
Michael Shi
Mary Ellen STEED
Mario Reinhard Stegert
Eugene Youchin TAN
Yongyu Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2012308993A1 publication Critical patent/AU2012308993A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012308993A 2011-09-15 2012-09-07 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients Abandoned AU2012308993A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535142P 2011-09-15 2011-09-15
US61/535,142 2011-09-15
PCT/US2012/054046 WO2013039764A1 (en) 2011-09-15 2012-09-07 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients

Publications (1)

Publication Number Publication Date
AU2012308993A1 true AU2012308993A1 (en) 2014-03-27

Family

ID=46846036

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012308993A Abandoned AU2012308993A1 (en) 2011-09-15 2012-09-07 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients

Country Status (12)

Country Link
US (1) US20140221389A1 (enExample)
EP (1) EP2755655A1 (enExample)
JP (1) JP2014526506A (enExample)
KR (1) KR20140062485A (enExample)
CN (1) CN103826634A (enExample)
AU (1) AU2012308993A1 (enExample)
BR (1) BR112014005653A2 (enExample)
CA (1) CA2848210A1 (enExample)
IN (1) IN2014DN02060A (enExample)
MX (1) MX2014003182A (enExample)
RU (1) RU2014114827A (enExample)
WO (1) WO2013039764A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
AU2020345791A1 (en) * 2019-09-11 2022-03-31 Inspirna, Inc. Methods of treating cancer
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
SG148864A1 (en) * 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
EP1631291B1 (en) * 2003-05-27 2009-08-12 Robert P. Hägerkvist Use of tyrosine kinase inhibitors to treat diabetes
EP1904480A2 (en) * 2005-05-23 2008-04-02 Novartis Pharma AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
EP2503888A4 (en) * 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION

Also Published As

Publication number Publication date
BR112014005653A2 (pt) 2017-03-28
JP2014526506A (ja) 2014-10-06
MX2014003182A (es) 2014-09-22
RU2014114827A (ru) 2015-10-20
KR20140062485A (ko) 2014-05-23
WO2013039764A1 (en) 2013-03-21
CN103826634A (zh) 2014-05-28
EP2755655A1 (en) 2014-07-23
IN2014DN02060A (enExample) 2015-05-15
US20140221389A1 (en) 2014-08-07
CA2848210A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
US20240261284A1 (en) Intermittent dosing of mdm2 inhibitor
JP6769982B2 (ja) Ｒａｓ変異と関連するがんの治療方法
EA034512B1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
WO2017201156A1 (en) Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
KR20250069693A (ko) 암 치료
CN103582479A (zh) 用pi3k抑制剂化合物治疗间皮瘤的方法
AU2012308993A1 (en) Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
US20230233695A1 (en) Mithramycin a nanoparticles for cancer treatment
US12383557B2 (en) Treatment of cancer using combination therapies comprising GDC-6036 and GDC-0077
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
WO2025103408A1 (zh) 治疗alk阳性或ros1阳性的非小细胞肺癌的方法
US20160367555A1 (en) Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease
CN119156216A (zh) 尼拉帕尼用于治疗脑癌的用途
US20240165120A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
Li Molecular imaging for characterization of lymphoma biology and monitoring response to cancer drug therapy
WO2011066545A1 (en) Treatment of human osteosarcoma

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted